ATE483976T1 - Gfats als modifikatoren des p53-wegs und verwendungsverfahren - Google Patents

Gfats als modifikatoren des p53-wegs und verwendungsverfahren

Info

Publication number
ATE483976T1
ATE483976T1 AT02749774T AT02749774T ATE483976T1 AT E483976 T1 ATE483976 T1 AT E483976T1 AT 02749774 T AT02749774 T AT 02749774T AT 02749774 T AT02749774 T AT 02749774T AT E483976 T1 ATE483976 T1 AT E483976T1
Authority
AT
Austria
Prior art keywords
methods
gfats
pathway
pathway modifiers
modifiers
Prior art date
Application number
AT02749774T
Other languages
English (en)
Inventor
Lori Friedman
Gregory Plowman
Marcia Belvin
Helen Francis-Lang
Danxi Li
Roel Funke
Original Assignee
Exelixis Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Exelixis Inc filed Critical Exelixis Inc
Application granted granted Critical
Publication of ATE483976T1 publication Critical patent/ATE483976T1/de

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5752—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the lungs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
    • C12Q1/42—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase involving phosphatase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/48—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase
    • C12Q1/485—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase involving kinase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/527—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving lyase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5014—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing toxicity
    • G01N33/5017—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing toxicity for testing neoplastic activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/5308—Immunoassay; Biospecific binding assay; Materials therefor for analytes not provided for elsewhere, e.g. nucleic acids, uric acid, worms, mites
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57515—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the breast
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57535—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the large intestine, e.g. colon, rectum or anus
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57545—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the ovaries
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57575—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving oncogenic proteins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G01N33/57595—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites involving intracellular compounds
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4739—Cyclin; Prad 1
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/575—Hormones
    • G01N2333/62—Insulins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/82—Translation products from oncogenes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/91—Transferases (2.)
    • G01N2333/912—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/988—Lyases (4.), e.g. aldolases, heparinase, enolases, fumarase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/10—Screening for compounds of potential therapeutic value involving cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2510/00—Detection of programmed cell death, i.e. apoptosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Analytical Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Pathology (AREA)
  • Cell Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Toxicology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
AT02749774T 2001-06-05 2002-06-02 Gfats als modifikatoren des p53-wegs und verwendungsverfahren ATE483976T1 (de)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US29607601P 2001-06-05 2001-06-05
US32860501P 2001-10-10 2001-10-10
US35725302P 2002-02-15 2002-02-15
PCT/US2002/021112 WO2002099083A2 (en) 2001-06-05 2002-06-02 Gfats as modifiers of the p53 pathway and methods of use

Publications (1)

Publication Number Publication Date
ATE483976T1 true ATE483976T1 (de) 2010-10-15

Family

ID=27404397

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02749774T ATE483976T1 (de) 2001-06-05 2002-06-02 Gfats als modifikatoren des p53-wegs und verwendungsverfahren

Country Status (8)

Country Link
US (7) US20030036076A1 (de)
EP (7) EP1456650B1 (de)
JP (7) JP2005501528A (de)
AT (1) ATE483976T1 (de)
AU (17) AU2002320264B2 (de)
CA (7) CA2449289A1 (de)
DE (1) DE60237917D1 (de)
WO (27) WO2002099083A2 (de)

Families Citing this family (121)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1402058A4 (de) * 2001-06-05 2006-02-01 Exelixis Inc Dgks als modifikatoren des p53-wegs und verwendungsverfahren
US20050008643A1 (en) * 2001-06-27 2005-01-13 Ora Bernard Diagnostic methods and agents
AU2003213606A1 (en) * 2002-03-01 2003-10-13 Exelixis, Inc. MP53s AS MODIFIERS OF THE p53 PATHWAY AND METHODS OF USE
GB0207533D0 (en) * 2002-04-02 2002-05-08 Oxford Glycosciences Uk Ltd Protein
EP1552845A4 (de) * 2002-06-26 2006-06-07 Takeda Pharmaceutical Mittel zur prävention/behandlung von krebs
FR2844713A1 (fr) * 2002-09-25 2004-03-26 Exonhit Therapeutics Sa Nouvelle cible de l'angiogenese et utilisations
US7358262B2 (en) 2003-01-29 2008-04-15 Whitehead Institute For Biomedical Research Identification of genotype-selective anti-tumor agents
WO2004067721A2 (en) * 2003-01-29 2004-08-12 Exelixis Inc. Tkts as modifiers of the beta-catenin pathway and methods of use
US7767387B2 (en) * 2003-06-13 2010-08-03 Sagres Discovery, Inc. Therapeutic targets in cancer
EP1599584B1 (de) * 2003-02-27 2009-07-01 Basf Se Modifizierte nitrilasen und deren verwendung in verfahren zur herstellung von carbonsäuren
EP1633856A4 (de) * 2003-06-19 2007-07-18 Exelixis Inc Marks als modifikatoren des pten-wegs und verwendungsverfahren
US8273536B2 (en) 2003-06-19 2012-09-25 Exelixis, Inc. Marks as modifers of the PTEN pathway and methods of use
US7435808B2 (en) 2003-06-25 2008-10-14 Bristol-Myers Squibb Company Polynucleotides encoding novel adiponectin receptor variant, AdipoR2v2
WO2005026737A2 (en) * 2003-09-18 2005-03-24 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with organic cation transporter slc22a4 (slc22a4)
WO2005029085A2 (en) * 2003-09-22 2005-03-31 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with organic cation transporter slc22a11 (slc22a11)
US20070053913A1 (en) * 2003-09-27 2007-03-08 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with g-protein coupled receptor adipor2 (adipor2)
WO2005040827A2 (en) * 2003-10-21 2005-05-06 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with organic cationic transporter-like 4 (orctl4) (orctl4)
WO2005040830A1 (en) * 2003-10-21 2005-05-06 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with organic cationic transporter-like 3 (orctl3) (orctl3)
ES2605443T3 (es) 2003-11-06 2017-03-14 Seattle Genetics, Inc. Conjugados de auristatina con anticuerpos anti-HER2 o anti-CD22 y su uso en terapia
WO2005052132A2 (en) * 2003-11-24 2005-06-09 Exelixis, Inc Mbms as modifiers of branching morphogenesis and methods of use
GB0328928D0 (en) * 2003-12-12 2004-01-14 Cancer Rec Tech Ltd Materials and methods relating to cell cycle control
US8415315B2 (en) 2004-05-06 2013-04-09 University Of Central Florida Research Foundation, Inc. Methods and compositions for inhibiting the proliferation of cancer cells
CA2568201C (en) 2004-05-24 2013-07-30 Universitat Zu Koln Identification of ergothioneine transporter and therapeutic uses thereof
NZ551180A (en) 2004-06-01 2009-10-30 Genentech Inc Antibody drug conjugates and methods
JP2008513015A (ja) * 2004-09-17 2008-05-01 エクセリクシス, インク. Rac経路のモディファイヤーとしてのpik4caおよび使用方法
TR201808537T4 (tr) 2004-09-23 2018-07-23 Genentech Inc Sistein değiştirilmiş antikorlar ve konjugatlar.
US20100111856A1 (en) 2004-09-23 2010-05-06 Herman Gill Zirconium-radiolabeled, cysteine engineered antibody conjugates
EP1817328A2 (de) * 2004-11-24 2007-08-15 Theraptosis S.A. Neue, als dual-caspase-2/6-inhibitoren nützliche peptide und deren biologische anwendungen
JP4993645B2 (ja) 2004-12-01 2012-08-08 ジェネンテック, インコーポレイテッド 抗体薬剤結合体および方法
JP5143566B2 (ja) * 2004-12-21 2013-02-13 ヴィヴェンティア バイオテクノロジーズ インコーポレーティッド 癌特異的抗体および細胞表面タンパク質
BRPI0607306A2 (pt) 2005-01-25 2009-08-25 Prolexys Pharmaceuticals Inc derivados de quinoxalina como agentes anti-tumor
WO2006094293A2 (en) * 2005-03-03 2006-09-08 President And Fellows Of Harvard College Slim compositions and methods of use thereof
EP1734118A1 (de) * 2005-06-15 2006-12-20 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Genom-weites RNAi-Screening zur Identifizierung von Genen die das JAK/STAT Pathway modulieren
JPWO2007037538A1 (ja) * 2005-09-30 2009-04-16 リンク・ジェノミクス株式会社 Spo11遺伝子の治療的又は診断的用途
CA2636990A1 (en) * 2006-01-13 2007-07-26 Battelle Memorial Institute Animal model for assessing copd-related diseases
WO2008068827A1 (ja) * 2006-12-01 2008-06-12 J-Pharma Co., Ltd. 腎臓特異性を有する新規な有機イオントランスポーター
EP1978105A1 (de) * 2007-04-04 2008-10-08 Deutsches Institut Für Ernährungsforschung - Stiftung Des Öffentlichen Rechts - Vertreten Durch Den Stiftungsvorstand TBC1D1 als Marker für die Reaktion auf Nahrungsfett und Fettleibigkeit
EP2023144A1 (de) * 2007-08-01 2009-02-11 Sanofi-Aventis Neues AS160-Protein, Testsysteme, Verfahren und Verwendungen bei der Identifizierung von Therapeutika gegen Typ-2-Diabetes
ES2557931T3 (es) 2007-08-08 2016-01-29 Lexicon Pharmaceuticals, Inc. (7H-Pirrolo[2,3-d]pirimidin-4-il)-piperazinas como inhibidores de cinasas para el tratamiento de cáncer e inflamación
EP2187217B1 (de) * 2007-08-24 2013-11-06 Lsip, Llc Verfahren zur erkennung von gynäkologischem krebs
EP2297153B1 (de) 2008-04-21 2015-05-27 Lexicon Pharmaceuticals, Inc. Limk2-inhibitoren, zusammensetzungen, die diese enthalten, und verfahren zu deren anwendung
AU2009270988A1 (en) 2008-07-15 2010-01-21 Genentech, Inc. Anthracycline derivative conjugates, process for their preparation and their use as antitumor compounds
AU2010292172A1 (en) 2009-09-09 2012-05-03 Centrose, Llc Extracellular targeted drug conjugates
CA2786730A1 (en) 2010-01-22 2011-07-28 Lexicon Pharmaceuticals, Inc. 5-(1h-pyrazol-5-yl)thiazole-based compounds for the treatment of diseases and disorders of the eye
PT2528625E (pt) 2010-04-15 2013-10-17 Spirogen Sarl Pirrolobenzodiazepinas e conjugados das mesmas
CA3220104A1 (en) 2010-06-08 2011-12-15 Genentech, Inc. Cysteine engineered antibodies and conjugates
WO2012010240A1 (en) * 2010-07-19 2012-01-26 Cellzome Ag In vivo method for the evaluation of a compound-target interaction
EP2640727B1 (de) 2010-11-17 2015-05-13 Genentech, Inc. Alaninylmaytansinol-antikörperkonjugate
WO2012131297A1 (en) 2011-03-28 2012-10-04 Jonathan Bayldon Baell Pyrido [3',2' :4,5] thieno [3, 2-d] pyrimidin- 4 - ylamine derivatives and their therapeutical use
EP2707723B1 (de) 2011-05-12 2016-02-10 Genentech, Inc. Lc-ms/ms-verfahren mit mehrfachreaktionsüberwachung zur erkennung therapeutischer antikörper in tierischen proben mittels rahmensignaturpeptiden
JP6104257B2 (ja) 2011-10-14 2017-03-29 メドイミューン・リミテッドMedImmune Limited ピロロベンゾジアゼピンおよびそのコンジュゲート
FR2984362B1 (fr) * 2011-12-20 2017-11-24 Biomerieux Sa Procede pour le diagnostic ou le pronostic in vitro du cancer du poumon
WO2013130093A1 (en) 2012-03-02 2013-09-06 Genentech, Inc. Biomarkers for treatment with anti-tubulin chemotherapeutic compounds
EP2825209B1 (de) 2012-03-14 2018-08-29 University of Central Florida Research Foundation, Inc. Neurofibromatose-therapeutika und screening dafür
EP2906297B1 (de) 2012-10-12 2017-12-06 ADC Therapeutics SA Pyrrolobenzodiazepin-antikörper-konjugate
KR101995620B1 (ko) 2012-10-12 2019-07-03 에이디씨 테라퓨틱스 에스에이 피롤로벤조디아제핀-항체 컨주게이트
PT2906253T (pt) 2012-10-12 2018-11-05 Medimmune Ltd Conjugados de anticorpo anti-psma de pirrolobenzodiazepina
BR112015008238A2 (pt) 2012-10-12 2017-11-28 Adc Therapeutics Sarl conjugados de pirrolbenzodiazepina-anticorpo anti-cd22
DK2906298T3 (en) 2012-10-12 2018-12-17 Adc Therapeutics Sa Pyrrolobenzodiazepine-antibody conjugates
WO2014057114A1 (en) 2012-10-12 2014-04-17 Adc Therapeutics Sàrl Pyrrolobenzodiazepine-anti-psma antibody conjugates
DK2839860T3 (da) 2012-10-12 2019-06-17 Medimmune Ltd Pyrrolobenzodiazepiner og konjugater deraf
US8959767B2 (en) 2012-11-21 2015-02-24 United Technologies Corporation Method of extending life of rotating parts
US9567340B2 (en) 2012-12-21 2017-02-14 Medimmune Limited Unsymmetrical pyrrolobenzodiazepines-dimers for use in the treatment of proliferative and autoimmune diseases
AU2013366493B2 (en) 2012-12-21 2017-08-24 Medimmune Limited Pyrrolobenzodiazepines and conjugates thereof
MX363787B (es) 2013-03-13 2019-04-03 Medimmune Ltd Pirrolobenzodiazepinas y conjugados de los mismos.
KR102066318B1 (ko) 2013-03-13 2020-01-14 메디뮨 리미티드 피롤로벤조디아제핀 및 그의 컨쥬게이트
ES2687439T3 (es) 2013-03-13 2018-10-25 Medimmune Limited Pirrolobenzodiazepinas y conjugados de las mismas
BR112016002829A2 (pt) 2013-08-12 2017-09-19 Genentech Inc Composto e processo para preparar o composto de conjugado anticorpo-¿droga, composição farmacêutica, método de tratamento do câncer, kit para o tratamento do câncer, intermediário ligante¿-droga, porção e composto de porção droga de dímero cbi
GB201317982D0 (en) 2013-10-11 2013-11-27 Spirogen Sarl Pyrrolobenzodiazepines and conjugates thereof
US10010624B2 (en) 2013-10-11 2018-07-03 Medimmune Limited Pyrrolobenzodiazepine-antibody conjugates
WO2015052535A1 (en) 2013-10-11 2015-04-16 Spirogen Sàrl Pyrrolobenzodiazepine-antibody conjugates
WO2015052534A1 (en) 2013-10-11 2015-04-16 Spirogen Sàrl Pyrrolobenzodiazepine-antibody conjugates
BR112016012410A2 (pt) 2013-12-16 2017-09-26 Genentech Inc conjugado de droga e anticorpo, composto conjugado de droga e anticorpo, composto não-peptídico, método de tratamento de doenças em seres humanos e composição farmacêutica
UA118113C2 (uk) 2013-12-16 2018-11-26 Дженентек, Інк. Пептидоміметичні сполуки та їх кон'югати антитіла з лікарським засобом
JP6980384B2 (ja) 2013-12-16 2021-12-15 ジェネンテック, インコーポレイテッド 1−(クロロメチル)−2,3−ジヒドロ−1h−ベンゾ[e]インドール二量体抗体−薬物コンジュゲート化合物、並びに使用及び処置の方法
EP3572425A1 (de) * 2013-12-17 2019-11-27 AIMM Therapeutics B.V. Vorrichtung und verfahren gegen myeloproliferative oder lymphoproliferative erkrankungen
EP3193940A1 (de) 2014-09-10 2017-07-26 Medimmune Limited Pyrrolobenzodiazepine und konjugate daraus
US10149913B2 (en) 2014-09-12 2018-12-11 Genentech, Inc. Anthracycline disulfide intermediates, antibody-drug conjugates and methods
GB201416112D0 (en) 2014-09-12 2014-10-29 Medimmune Ltd Pyrrolobenzodiazepines and conjugates thereof
JP2017531620A (ja) 2014-09-12 2017-10-26 ジェネンテック, インコーポレイテッド システイン操作抗体及びコンジュゲート
JP2017533887A (ja) 2014-09-17 2017-11-16 ジェネンテック, インコーポレイテッド ピロロベンゾジアゼピン類及びその抗体ジスルフィドコンジュゲート
CN107148285B (zh) 2014-11-25 2022-01-04 Adc治疗股份有限公司 吡咯并苯并二氮杂䓬-抗体缀合物
CA2969689A1 (en) 2014-12-03 2016-06-09 Genentech, Inc. Quaternary amine compounds and antibody-drug conjugates thereof
GB201506411D0 (en) 2015-04-15 2015-05-27 Bergenbio As Humanized anti-axl antibodies
GB201506402D0 (en) 2015-04-15 2015-05-27 Berkel Patricius H C Van And Howard Philip W Site-specific antibody-drug conjugates
IL292697A (en) * 2015-06-19 2022-07-01 Immatics Biotechnologies Gmbh New peptides and their combination for use in immunotherapy and methods for creating supports for use against pancreatic cancer and other types of cancer
CR20180243A (es) 2015-10-02 2018-07-31 Genentech Inc Conjugados de anticuerpo-fármaco de pirrolobenzodiazepina y métodos de uso
MA43354A (fr) 2015-10-16 2018-08-22 Genentech Inc Conjugués médicamenteux à pont disulfure encombré
JP6852065B2 (ja) 2015-10-20 2021-03-31 ジェネンテック, インコーポレイテッド カリケアマイシン−抗体−薬物コンジュゲート及び使用方法
GB201601431D0 (en) 2016-01-26 2016-03-09 Medimmune Ltd Pyrrolobenzodiazepines
GB201602356D0 (en) 2016-02-10 2016-03-23 Medimmune Ltd Pyrrolobenzodiazepine Conjugates
GB201602359D0 (en) 2016-02-10 2016-03-23 Medimmune Ltd Pyrrolobenzodiazepine Conjugates
CN108700598A (zh) 2016-03-25 2018-10-23 豪夫迈·罗氏有限公司 多路总抗体和抗体缀合的药物量化测定法
GB201607478D0 (en) 2016-04-29 2016-06-15 Medimmune Ltd Pyrrolobenzodiazepine Conjugates
CN109152843A (zh) 2016-05-20 2019-01-04 豪夫迈·罗氏有限公司 Protac抗体缀合物及其使用方法
CN109313200B (zh) 2016-05-27 2022-10-04 豪夫迈·罗氏有限公司 用于表征位点特异性抗体-药物缀合物的生物分析性方法
JP7043425B2 (ja) 2016-06-06 2022-03-29 ジェネンテック, インコーポレイテッド シルベストロール抗体-薬物コンジュゲート及び使用方法
WO2018031662A1 (en) 2016-08-11 2018-02-15 Genentech, Inc. Pyrrolobenzodiazepine prodrugs and antibody conjugates thereof
JP7050770B2 (ja) 2016-10-05 2022-04-08 エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト 抗体薬物コンジュゲートの調製方法
GB201617466D0 (en) 2016-10-14 2016-11-30 Medimmune Ltd Pyrrolobenzodiazepine conjugates
GB201702031D0 (en) 2017-02-08 2017-03-22 Medlmmune Ltd Pyrrolobenzodiazepine-antibody conjugates
RS61795B1 (sr) 2017-02-08 2021-06-30 Adc Therapeutics Sa Konjugati pirolobenzodiazepin antitela
SMT202200490T1 (it) 2017-04-18 2023-01-13 Medimmune Ltd Coniugati di pirrolobenzodiazepina
WO2018193102A1 (en) 2017-04-20 2018-10-25 Adc Therapeutics Sa Combination therapy with an anti-axl antibody-drug conjugate
KR102442736B1 (ko) 2017-06-14 2022-09-16 에이디씨 테라퓨틱스 에스에이 항-cd19 adc의 투여를 위한 투약량 체제
SI3668874T1 (sl) 2017-08-18 2022-04-29 Medimmune Limited Pirolobenzodiazepinski konjugati
ES3075078T3 (es) 2017-09-20 2026-07-27 Ph Pharma Co Ltd Análogos de tailanstatina
GB201803342D0 (en) 2018-03-01 2018-04-18 Medimmune Ltd Methods
GB201806022D0 (en) 2018-04-12 2018-05-30 Medimmune Ltd Pyrrolobenzodiazepines and conjugates thereof
GB201814281D0 (en) 2018-09-03 2018-10-17 Femtogenix Ltd Cytotoxic agents
AU2019365238A1 (en) 2018-10-24 2021-05-13 F. Hoffmann-La Roche Ag Conjugated chemical inducers of degradation and methods of use
EP3894427A1 (de) 2018-12-10 2021-10-20 Genentech, Inc. Photovernetzende peptide zur stellenspezifischen konjugation an fc-haltige proteine
GB201901197D0 (en) 2019-01-29 2019-03-20 Femtogenix Ltd G-A Crosslinking cytotoxic agents
JP7232925B2 (ja) 2019-02-15 2023-03-03 ウーシー バイオロジクス アイルランド リミテッド 改善された均一性を有する抗体薬物コンジュゲートの調製するプロセス
CN113631560B (zh) 2019-03-15 2025-02-18 麦迪穆有限责任公司 氮杂环丁烷并苯并二氮杂䓬二聚体和用于治疗癌症的包含它们的缀合物
GB2597532A (en) 2020-07-28 2022-02-02 Femtogenix Ltd Cytotoxic compounds
CN117980327A (zh) 2021-11-03 2024-05-03 杭州多禧生物科技有限公司 抗体的特异性偶联
CN120417934A (zh) 2022-12-23 2025-08-01 基因泰克公司 Cereblon降解剂缀合物及其用途
KR20260012304A (ko) 2023-04-17 2026-01-26 피크 바이오, 인크. 항체 및 항체-약물 접합체 및 사용 방법 및 합성 공정 및 중간체
WO2026006688A2 (en) 2024-06-28 2026-01-02 Firefly Bio, Inc. Degrader antibody conjugates and uses thereof
TW202617186A (zh) 2024-06-28 2026-05-01 美商飛爾富來生物公司 Bcl-xl降解劑抗體結合物及其用途

Family Cites Families (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4873191A (en) 1981-06-12 1989-10-10 Ohio University Genetic transformation of zygotes
US4870009A (en) 1982-11-22 1989-09-26 The Salk Institute For Biological Studies Method of obtaining gene product through the generation of transgenic animals
US4670388A (en) 1982-12-30 1987-06-02 Carnegie Institution Of Washington Method of incorporating DNA into genome of drosophila
US4736866B1 (en) 1984-06-22 1988-04-12 Transgenic non-human mammals
US4945050A (en) 1984-11-13 1990-07-31 Cornell Research Foundation, Inc. Method for transporting substances into living cells and tissues and apparatus therefor
US5235033A (en) * 1985-03-15 1993-08-10 Anti-Gene Development Group Alpha-morpholino ribonucleoside derivatives and polymers thereof
US5421964A (en) * 1993-04-30 1995-06-06 E. I. Du Pont De Nemours And Company Process for separating HCl and halocarbons
US5989893A (en) * 1993-09-27 1999-11-23 University Of Massachusetts Medical Center Receptor-activated reporter systems
EP0734439A4 (de) * 1993-11-22 2000-07-12 Onyx Pharma Inc p53-bindende Polypeptide und Polynucleotide die für diese kodieren
US5659024A (en) * 1994-01-14 1997-08-19 The Burnham Institute Promotors that regulate the expression of genes involved in cell death
DE69535901D1 (de) * 1994-10-28 2009-01-29 Max Planck Gesellschaft Proteinkinase npk-110
US6218162B1 (en) * 1995-09-27 2001-04-17 Gerald Krystal SH2-containing inositol-phosphatase
US5863729A (en) * 1996-07-09 1999-01-26 Washington University DNA sequences encoding human TcAK1 kinase
US5876713A (en) * 1996-08-13 1999-03-02 Takeda Chemical Industries Ltd Glutamine: fructose-6-phosphate amidotransferase, its production and use
US5962303A (en) * 1996-10-15 1999-10-05 Smithkline Beecham Corporation Topoisomerase III
SE9604731D0 (sv) * 1996-12-20 1996-12-20 Tamas Bartfai Konsulting Ab A component of intercellular junctions in the endothelium
JPH10257896A (ja) * 1997-01-17 1998-09-29 Seikagaku Kogyo Co Ltd グリコサミノグリカン硫酸基転移酵素のポリペプチド及びそれをコードするdna
CA2203083A1 (en) * 1997-04-18 1998-10-18 Gail Ouellette Gene and cdna involved in alzheimer's disease
US5955338A (en) * 1997-06-27 1999-09-21 Incyte Pharmaceuticals, Inc. Phosphatidylinositol 4,5-bisphosphate 5-phosphatase
AU8382998A (en) * 1997-07-02 1999-01-25 Genzyme Corporation P53 influenced gene expression
US6133246A (en) * 1997-08-13 2000-10-17 Isis Pharmaceuticals Inc. Antisense oligonucleotide compositions and methods for the modulation of JNK proteins
US5977311A (en) * 1997-09-23 1999-11-02 Curagen Corporation 53BP2 complexes
US6203788B1 (en) * 1997-09-29 2001-03-20 Adherex Inc. Compounds and methods for regulating cell adhesion
AUPO957397A0 (en) * 1997-10-01 1997-10-30 St. Vincent's Institute Of Medical Research Transporter protein
WO1999029860A1 (en) * 1997-12-08 1999-06-17 Ontogeny, Inc. Cadherin-like polypeptides, methods and compositions related thereto
EP1037992A1 (de) * 1997-12-15 2000-09-27 Institut National De La Sante Et De La Recherche Medicale (Inserm) Rb18a sogennantes p53 regulatorisches protein, und dessen verwendungen
US6506559B1 (en) 1997-12-23 2003-01-14 Carnegie Institute Of Washington Genetic inhibition by double-stranded RNA
US5942398A (en) * 1998-02-26 1999-08-24 Millennium Pharmaceuticals, Inc. Nucleic acid molecules encoding glutx and uses thereof
US6214821B1 (en) * 1998-03-05 2001-04-10 Washington State University Research Foundation Methods and composition for the inhibition of cancer cells
US6020135A (en) * 1998-03-27 2000-02-01 Affymetrix, Inc. P53-regulated genes
US6165461A (en) * 1998-04-14 2000-12-26 Board Of Regents, University Of Texas System Tao protein kinases and methods of use therefor
EP1098968A4 (de) * 1998-07-20 2002-01-02 Univ Jefferson Homologe von nitrilase
WO2000010389A1 (en) * 1998-08-18 2000-03-02 The Uab Research Foundation BLOCKADE OF GLUCOSE TOXICITY TO THE β CELLS IN THE ISLETS OF LANGERHANS
WO2000031530A2 (en) * 1998-11-23 2000-06-02 The Government Of The United States Of America Represented By The Secretary, Department Of Health And Human Services Screening of nos2 moldulators using p53 miutant cells
WO2000037617A1 (en) * 1998-12-22 2000-06-29 G.D. Searle & Co. Glutamine: fructose-6-phosphate aminotransferase ii enzyme and their encoding nucleic acids
EP1165592A4 (de) 1999-03-16 2005-03-09 Exelixis Inc GENE UND PROTEINE DES TUMORSUPPRESSORS p53 VON INSEKTEN
WO2000061747A2 (en) * 1999-04-14 2000-10-19 Arbor Vita Corporation Clasp-2 transmembrane proteins
AU5173400A (en) * 1999-05-28 2000-12-18 Sugen, Inc. Protein kinases
US6558903B1 (en) * 1999-06-30 2003-05-06 Millennium Pharmaceuticals, Inc. Kinases and uses thereof
AU6091900A (en) * 1999-07-13 2001-01-30 Incyte Genomics, Inc. Human lim domain proteins
AU5840300A (en) * 1999-07-14 2001-01-30 University Of Lausanne Glutx polypeptide family and nucleic acids encoding same
AU6180900A (en) * 1999-07-29 2001-02-19 Chugai Seiyaku Kabushiki Kaisha Novel genes encoding protein kinase/protein phosphatase
CA2384115C (en) * 1999-09-03 2016-08-02 Brigham And Women's Hospital, Inc. Methods and compositions for treatment of inflammatory disease using cadherin-11 modulating agents
EP1222277A2 (de) * 1999-10-05 2002-07-17 Curagen Corporation Endozepine-ähnliche polypeptide und dafür kodierende polynukleotide
EP1235842A4 (de) 1999-10-15 2003-04-23 Univ Massachusetts Gene des rns-interferenzweges als hilfsmittel der gezielten gentischen interferenz
WO2001030964A2 (en) * 1999-10-22 2001-05-03 Lifespan Biosciences, Inc. Anti-cancer nucleic acid and protein targets
AU1466001A (en) * 1999-11-05 2001-05-14 Phase-1 Molecular Toxicology Methods of determining individual hypersensitivity to an agent
KR20020064901A (ko) 1999-11-24 2002-08-10 다케다 야쿠힌 고교 가부시키가이샤 질환관련 유전자의 용도
EP1240194A2 (de) * 1999-11-24 2002-09-18 Sugen, Inc. Protein kinasen und protein kinase-ahnliche enzyme identifiziert durch genomisches sequenzieren
EP1257578A2 (de) * 1999-12-23 2002-11-20 Incyte Genomics, Inc. Transporter und ionenkanäle
US6635742B1 (en) * 2000-01-25 2003-10-21 Nuvelo, Inc. Antibodies specific for semaphorin-like polypeptides
AU2001234944A1 (en) 2000-02-03 2001-08-14 Hyseq, Inc. Novel nucleic acids and polypeptides
AU2001238488A1 (en) * 2000-02-17 2001-08-27 Incyte Genomics, Inc. Human kinases
AU2001249064A1 (en) * 2000-02-22 2001-09-03 Mount Sinai School Of Medicine Of New York University N-cadherin modulated migration, invasion, and metastasis
US6420382B2 (en) * 2000-02-25 2002-07-16 Merck & Co., Inc. Tyrosine kinase inhibitors
US7001735B2 (en) * 2000-03-01 2006-02-21 Albert Einstein College Of Medicine Of Yeshiva University Glucose transporter/sensor protein and uses thereof
AU4592601A (en) * 2000-03-21 2001-10-03 Millennium Predictive Medicine Novel genes, compositions, kits, and method for identification, assessment, prevention, and therapy of ovarian cancer
US7196242B2 (en) * 2000-05-16 2007-03-27 The Regents Of The University Of California Methods for identifying novel therapeutics and diagnostics in the p53 pathway
DE10024171A1 (de) * 2000-05-17 2001-12-20 Basf Lynx Bioscience Ag Neuronale Serin-Threonin-Protein-Kinase
AU7634301A (en) * 2000-05-26 2001-12-03 Bayer Aktiengesellschaft Regulation of human p78-like serine/threonine kinase
AU2001268525A1 (en) 2000-06-15 2001-12-24 Incyte Genomics, Inc. Human kinases
WO2002010402A2 (en) * 2000-07-28 2002-02-07 Chiron Corporation Isolation of drosophila and human polynucleotides encoding par-1 kinase, polypeptides encoded by the polynucleotides and methods utilizing the polynucleotides and polypeptides
AU2002220633A1 (en) * 2000-10-16 2002-04-29 Bayer Aktiengesellschaft Regulation of human sulfotransferase
WO2002036755A2 (en) * 2000-10-30 2002-05-10 Bayer Aktiengesellschaft Regulation of human inositolpolyphosphate 5-phosphatase
WO2002090378A2 (en) * 2001-05-09 2002-11-14 Genaissance Pharmaceuticals, Inc. Haplotypes of the ces2 gene
CA2445611A1 (en) * 2001-05-31 2002-12-05 Chiron Corporation P-cadherin as a target for anti-cancer therapy
WO2003033708A2 (en) * 2001-10-15 2003-04-24 Bayer Healthcare Ag Regulation of human serine/threonine protein kinase
WO2003054190A1 (fr) * 2001-12-21 2003-07-03 Takeda Chemical Industries, Ltd. Nouvelles proteines et adn correspondants
AU2003224811A1 (en) * 2002-03-28 2003-10-13 Incyte Corporation Transporters and ion channels

Also Published As

Publication number Publication date
EP1404863A1 (de) 2004-04-07
JP2004537294A (ja) 2004-12-16
WO2002099056A3 (en) 2003-10-02
WO2002099051A3 (en) 2003-04-03
AU2002305797A1 (en) 2002-12-16
WO2002098890A3 (en) 2004-09-10
WO2002099050A2 (en) 2002-12-12
WO2002099044A2 (en) 2002-12-12
WO2002099058A2 (en) 2002-12-12
EP1456650A2 (de) 2004-09-15
EP1401861A2 (de) 2004-03-31
AU2002314884A1 (en) 2002-12-16
JP2005501528A (ja) 2005-01-20
EP1474687A4 (de) 2005-11-16
US20030013144A1 (en) 2003-01-16
EP1456650A4 (de) 2005-11-02
US20060160764A1 (en) 2006-07-20
WO2002099041A2 (en) 2002-12-12
AU2002312228A1 (en) 2002-12-16
AU2002312269A1 (en) 2002-12-16
WO2002099054A3 (en) 2005-03-31
WO2002099053A3 (en) 2005-04-21
AU2002312241A1 (en) 2002-12-16
EP1402067A2 (de) 2004-03-31
WO2002099046A3 (en) 2003-05-01
AU2002320052A8 (en) 2009-07-30
EP1401861A4 (de) 2005-04-27
EP1404863A4 (de) 2005-05-11
WO2002099057A2 (en) 2002-12-12
JP2004535191A (ja) 2004-11-25
WO2002098898A3 (en) 2003-07-03
WO2002098890A2 (en) 2002-12-12
WO2002099057A3 (en) 2003-07-24
WO2002098898A2 (en) 2002-12-12
US20020192695A1 (en) 2002-12-19
WO2002099053A2 (en) 2002-12-12
DE60237917D1 (de) 2010-11-18
WO2002099047A3 (en) 2004-02-26
JP2004528044A (ja) 2004-09-16
WO2002099044A3 (en) 2003-07-17
EP1404374A1 (de) 2004-04-07
US8153384B2 (en) 2012-04-10
AU2002312252A1 (en) 2002-12-16
WO2002099042A3 (en) 2003-07-31
AU2002312254A1 (en) 2002-12-16
AU2002305796A1 (en) 2002-12-16
US20080166709A1 (en) 2008-07-10
WO2002099048A2 (en) 2002-12-12
JP2004534539A (ja) 2004-11-18
WO2002099052A2 (en) 2002-12-12
WO2002099122A1 (en) 2002-12-12
EP1474687A2 (de) 2004-11-10
WO2002099140A1 (en) 2002-12-12
AU2002345490A1 (en) 2002-12-16
WO2002099055A3 (en) 2003-05-01
CA2449267A1 (en) 2002-12-12
WO2002099046A2 (en) 2002-12-12
WO2002099056A2 (en) 2002-12-12
CA2449270A1 (en) 2002-12-12
WO2002099055A2 (en) 2002-12-12
CA2449206A1 (en) 2002-12-12
AU2002303956A1 (en) 2002-12-16
WO2002099054A2 (en) 2002-12-12
WO2002099047A2 (en) 2002-12-12
JP2004536297A (ja) 2004-12-02
WO2002099059A2 (en) 2002-12-12
WO2002099049A3 (en) 2005-08-18
JP2005505255A (ja) 2005-02-24
WO2002099049A2 (en) 2002-12-12
WO2002099041A3 (en) 2003-10-30
CA2448250A1 (en) 2002-12-12
WO2002099083A2 (en) 2002-12-12
AU2002312255A1 (en) 2002-12-16
EP1463827A4 (de) 2005-11-09
WO2002099058A3 (en) 2009-06-11
AU2002312254A8 (en) 2005-11-17
CA2449425A1 (en) 2002-12-12
WO2002099083A3 (en) 2004-07-01
AU2002320052A1 (en) 2002-12-16
AU2002310271A1 (en) 2002-12-16
CA2448107A1 (en) 2002-12-12
CA2449289A1 (en) 2002-12-12
WO2002099059A3 (en) 2003-11-27
AU2002345500A1 (en) 2002-12-16
US20030036076A1 (en) 2003-02-20
WO2002098467A1 (en) 2002-12-12
WO2002099052A3 (en) 2003-04-03
US20030165809A1 (en) 2003-09-04
EP1463827A2 (de) 2004-10-06
WO2002099138A2 (en) 2002-12-12
EP1402067A4 (de) 2005-04-27
WO2002099125A1 (en) 2002-12-12
WO2002099427A1 (en) 2002-12-12
WO2002099051A2 (en) 2002-12-12
AU2002320264B2 (en) 2008-05-01
AU2002345497A1 (en) 2002-12-16
US20100325743A1 (en) 2010-12-23
WO2002099426A1 (en) 2002-12-12
EP1456650B1 (de) 2010-10-06
WO2002099138A3 (en) 2003-02-20
EP1404374A4 (de) 2005-04-27
WO2002099042A2 (en) 2002-12-12
WO2002099050A3 (en) 2004-03-11
AU2002318172A1 (en) 2002-12-16
WO2002099048A3 (en) 2004-07-22

Similar Documents

Publication Publication Date Title
DE60237917D1 (de) Gfats als modifikatoren des p53-wegs und verwendungsverfahren
WO2002099075A3 (en) Prmts as modifiers of the p53 pathway and methods of use
WO2003074662A3 (en) SCDs AS MODIFIERS OF THE p53 PATHWAY AND METHODS OF USE
WO2003014301A3 (en) Hprp4s as modifiers of the p53 pathway and methods of use
WO2002099043A3 (en) P5CRS AS MODIFIERS OF THE p53 PATHWAY AND METHODS OF USE
ATE536549T1 (de) Galnts als modifikatoren des igfr-weges und verwendungsverfahren
WO2003035831A3 (en) Lrrcaps as modifiers of the p53 pathway and methods of use
ATE494551T1 (de) C20orf23 als modifikator des igfr-wegs und verwendungsverfahren
ATE469175T1 (de) Prkcs als modifikatoren des beta catenin pfads und anwendungsverfahren

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties